News >

Treatment Discontinuation Achievable in Select Patients With CML

Angelica Welch
Published: Thursday, Oct 04, 2018

Ehab Atallah, MD

Ehab Atallah, MD

The majority of patients with chronic myeloid leukemia (CML) can expect a similar lifespan as the general population due to the advancements in therapy over the last few years. Now, the concern in the CML space is selecting optimal patients for treatment discontinuation, said Ehab Atallah, MD.

State of the Science Summit™ on Hematologic Malignancies, Atallah, associate professor of medicine, Division of Hematology and Oncology, Medical College of Wisconsin, discussed the discontinuation of treatment for patients with CML.

OncLive: What is the current state of CML care?

Atallah: CML has gone from a disease requiring transplant to now just needing a pill every day. Survival is similar to the general population, and the new paradigm is trying to get patients to stop therapy. The concept is called treatment-free remission. Now that patients are doing well, we want to get them off the drug, improve their quality of life, and reduce cost.

What studies have evaluated TKI discontinuation for patients with CML?

Going back to 2010, the first study [STIM1] had a carefully selected group of patients who were doing very well and in a deep remission stop their drug, and only half of them needed to restart. Based on that study, there have been multiple studies across the world that have enrolled more than 2000 patients. Now we know that this approach is safe for a select group of patients.

One of the studies that was done recently was the ENESTop trial. How this is different than all the other trials is it enrolled patients who were resistant to imatinib (Gleevec) or were on imatinib first and then switched to nilotinib (Tasigna). Not all patients were resistant to imatinib; some of them were physician-choice [switches] or were intolerant to imatinib and switched to nilotinib. Once these patients who received nilotinib were in a sustained deep molecular response, they stopped nilotinib. The rates of successful treatment-free remission are about 50%—so very similar to other studies for stopping TKIs in the frontline setting.

How do you decide whether therapy should be stopped in a given patient?

That is a very important question. The criteria for [discontinuation] are very clear in the NCCN guidelines. Patients have to be in a chronic-phase CML, not an advanced phase. They must be on-drug for at least 3 years and have a sustained deep molecular response. They also have to be compliant patients; they have to be willing to come in every month to get their lab checked for at least 6 months, and then every 2 months for 18 months. These are the patients who you would consider stopping therapy for.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication